Dianthus Therapeutics’ (DNTH) Outperform Rating Reiterated at Wedbush

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report issued on Wednesday,Benzinga reports. They presently have a $36.00 price target on the stock. Wedbush’s price target points to a potential upside of 58.45% from the stock’s current price.

Other research analysts have also issued research reports about the company. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Stock Down 2.8 %

Shares of DNTH stock traded down $0.66 during trading on Wednesday, reaching $22.72. The company’s stock had a trading volume of 43,258 shares, compared to its average volume of 244,145. The company has a market cap of $672.44 million, a price-to-earnings ratio of -9.09 and a beta of 1.82. Dianthus Therapeutics has a one year low of $18.13 and a one year high of $33.77. The business has a fifty day moving average price of $22.65 and a 200-day moving average price of $24.97.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Quest Partners LLC boosted its stake in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares during the period. Walleye Capital LLC acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at about $821,000. Finally, Braidwell LP grew its stake in shares of Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after acquiring an additional 126,836 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.